• Immune checkpoint inhibitors (ICIs) revolutionize oral cancer treatment, particularly in recurrent/metastatic cases. • It blocks PD-1/PD-L1 pathway and reactivating T cells to target cancer cells. • Combining ICIs with other modalities holds promise for synergistic effects and overcoming resistance. • Personalized approaches based on tumor biology, immune status, and genetic profile can further optimize therapeutic outcomes.
No takes yet. Share an insight, caveat, or question.
Ajay Guru (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: